Antibacterial Activity of New Dibenzoxepinone Oximes with Fluorine and Trifluoromethyl Group Substituents by Limban, Carmen & Chifiriuc, Mariana Carmen
Int. J. Mol. Sci. 2011, 12, 6432-6444; doi:10.3390/ijms12106432 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
Antibacterial Activity of New Dibenzoxepinone Oximes with 
Fluorine and Trifluoromethyl Group Substituents 
Carmen Limban 
1 and Mariana Carmen Chifiriuc 
2,3,* 
1  Pharmaceutical Chemistry Department, Faculty of Pharmacy, “Carol Davila” University of 
Medicine and Pharmacy, 6 Traian Vuia, Bucharest 020956, Romania;  
E-Mail: carmen_limban@yahoo.com 
2  Microbiology Immunology Department, Faculty of Biology, University of Bucharest,  
Ale. Portocalelor 1-3, Buhcarest 60101, Romania 
3  National Institute of Research and Development for Microbiology and Immunology Cantacuzino, 
103 Spl. Independentei, Bucharest 060631, Romania 
*  Author to whom correspondence should be addressed; E-Mail: carmen_balotescu@yahoo.com; 
Tel.: +40-766728315; Fax: +40-0213181566 
Received: 21 July 2011; in revised form: 29 August 2011 / Accepted: 14 September 2011 / 
Published: 28 September 2011 
 
Abstract: In this paper we present the antimicrobial activity of some newly synthesized 
dibenz[b,e]oxepin  derivatives  bearing  the  oximino  moiety,  and  fluorine  (F)  and 
trifluoromethyl (CF3) group substituents. The chemical  structure and purity of the  new 
compounds were assessed by using elemental analysis, NMR and FTIR spectroscopy. The 
new compounds were screened for their antibacterial activity towards Gram-positive and 
Gram-negative strains, by qualitative and quantitative assays. Our results demonstrated that 
the CF3 and F disubstituted compounds could be considered for the further development of 
novel antimicrobial drugs.  
Keywords: dibenz[b,e]oxepin; methanone derivatives; antibacterial activity; gram-positive; 
gram-negative 
 
1. Introduction  
Dibenz[b,e]oxepin  derivatives  represent  an  interesting  class  of  compounds  possessing  a  wide 
spectrum of biological and pharmacological activities, such as antidepressant, anxiolytic, anticholinergic 
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and  antihistaminic  [1,2],  antipsychotic  [3]  and  also  analgesic,  antipyretic  and  anti-inflammatory 
properties [4,5]. On the other hand,  the oximino moiety has been also reported to have  biological 
significance, being included as a structural fragment in Noxiptilin, an antidepressant drug. 
A series of new imidazole derivatives of 6,11-dihydrodibenz[b,e]oxepines [6] have been proved to 
exhibit antifungal activity. Leptosphaerin D, an analogue of Arugosin F,  is a new polyketide with 
dibenz[b,e]oxepin structure, isolated from solid cultures of the ascomycete fungus Leptosphaeria sp., 
which showed antifungal effects against the plant pathogens Fusarium nivale and Piricularia oryzae [7]. 
Fluoro  and  trifluoromethylated  compounds  are  of  particular  interest  as  the  strong  
electron-withdrawing effect of F and CF3 groups contributes to a number of biologically important 
molecular  properties.  Some  of  the  most  well  known  fluorine-containing  drugs  with  antibacterial 
activity are the fluoroquinolones. The isosteric substitution of hydrogen by fluorine in organofluorines 
compounds may increase the lipophilicity and thus enhance the rate of cell penetration, which is a very 
important feature in drug delivery, both referring to prokaryotic, Gram-negative bacteria as well as 
eukaryotic cells. The higher polarizability due to the C-F bond may give rise to new possibilities for 
binding  to  the  receptor.  Fluorine  substitution  can  also  influence  pharmacokinetic  and 
pharmacodynamic properties of the molecule [8].  
The  aim  of  the  present  study  was  to  synthesize  ({[(E/Z)-11-dibenz[b,e]oxepin-11(6H)-
ylidene]amino}oxy)(substituted-phenyl)methanone derivatives, the phenyl group being disubstituted in 
different positions with fluorine and trifluoromethyl group, in the purpose to obtain hybrid molecules 
bearing  pharmacophore  groups,  i.e.,  dibenz[b,e]oxepin  nucleus,  oximino  moiety,  fluorine  and 
trifluoromethyl group, with improved antimicrobial activity. 
2. Results and Discussion  
Taking  into  account  that,  until  now,  the  potential  biological  activities  of  different 
dibenz[b,e]oxepins derivatives have been tested almost exclusively on eukaryotic cells (i.e., yeasts, 
molds, protozoan and mammalian cells), our purpose was to assess the in vitro antimicrobial activity of 
dibenz[b,e]oxepins  carrying  oximino  group  at  position  11,  as  well  as  fluorine  and  trifluoromethyl 
groups as substituents, using Gram-positive and Gram-negative bacterial strains, recently isolated from 
different clinical sources and resistant to beta-lactam antibiotics.  
2.1. Synthesis and Chemical Characterization  
The structure of the new compounds was established on the basis of the elemental analysis and 
spectral (FTIR and NMR) data. 
The new compounds were solid, crystallized, white or light yellow, soluble at normal temperature 
in acetone, benzene, toluene, xylene, chloroform, dichloromethane and dichloroethane, by heating in 
inferior alcohols, insoluble in water. The melting points indicated the purity of the new compounds and 
the elemental analysis closely corresponded to the calculated values.  
Structural elucidation of these compounds was also performed by IR and NMR spectra, with all 
results being in full agreement with the proposed structures. 
The IR spectra were given as w—weak band; m—medium band; s—intense band; vs—very intense 
band and were obtained using the ATR technique. In the IR spectra some significant stretching bands Int. J. Mol. Sci. 2011, 12                       
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due  to  υC=N  and  υN–O  were  observed  at  1597–1611  cm
−1  and  971–1002  cm
−1,  respectively.  The 
caracteristic  bands  for  the  –CH2–O–  moiety  are:  νCH2  sym:  2865–2897  cm
−1;  νCH2  asym:  
2962–3001  cm
−1;  δCH2  sym:  1304–1310  cm
−1;  δCH2  asym:  1480–1482  cm
−1;  νC–O–C  sym:  
945–988 cm
−1; νC–O–C asym: 1075–1107 cm
−1. The IR spectra revealed the presence of –O–C=O 
absorption bands as νC=O in the region 1740–1764 cm
−1 and the νC–O at about 1207–1257 cm
−1. The 
aromatic  rings  appeared  as  ν=C–H  in  the  region  3068–3079  cm
−1  and  νC=C  at  1440–1611  cm
−1. 
Halogen  presence,  in  the  molecules  of  new  compounds,  is  proved  by  stretching  bands  situated  at  
1001–1098 cm
−1 (for νCar–F). 
The structure of the new compounds is also supported by NMR spectra. The new dibenzoxepins 
were dissolved in CDCl3 and the chemical shifts values, expressed in parts per million (ppm) were 
referenced downfield to tetramethylsilane, for 
1H-NMR and 
13C-NMR and upfield to trifluorocetic acid 
(δ = −76.20 ppm) for 
19F-NMR and the coupling constants (J) values in Hertz. 
The chemical shifts for hydrogen and carbon atoms were established also by Apt, Gcosy, Ghmqc, 
Ghmbc experiments. 
The 
1H-NMR  data  were  reported  in  the  following  order:  chemical  shifts,  number  of  protons, 
multiplicity  (s,  singlet;  d,  doublet;  dd,  double  doublet;  dq,  double  quartet;  ddd,  doublet of  double 
doublets; td, triple doublet; t, triplet; q, quartet, m, multiplet; b, broad), the coupling constants and 
signal/atom attribution, the signals attribution presenting the major (
M) and minor (
m) signals, produced 
by the E/Z isomerism. 
The presence of an oxygen atom in the fifth position makes possible the existence of E/Z isomery, 
materialized in our spectra through the dedoublation of some of the protons and the carbon signals. 
Analyzing  the  chemical  shifts  of  the  dibenz[b,e]oxepin  scaffold  in  the 
1H-NMR  spectra,  CH2O 
protons appeared as a singlet at 5.25–5.26 ppm as minor signal and 5.19–5.20 ppm as major signal.  
Also,  the 
13C-NMR  spectra  displayed  the  characteristic  signal  of  the  suggested  structures.  The 
signal at about 165.09–165.88 ppm, is attributed to C-11, the most unscreened carbon atom. The signal 
of the carbonyl carbon appears in the range of 161.14–165.08 ppm. The C-19 can be found in the range 
of 121.25–123.46 ppm as quartet. The methylene group (C-6) appears in the range of 70.48–70.61 ppm 
as major signal and 70.42–70.59 ppm as minor signal the differences between the chemical shifts of 
the two E/Z isomers are insignificant.  
2.2. Antimicrobial Activity Results  
Until now, dibenz[b,e]oxepins have not been deeply investigated for their antimicrobial activities by 
other  authors.  However,  there  are  documented  a  series  of  other  biological  activities  for  these 
compounds, demonstrating their interaction with the eukariotic cells, also explaining their antifungal 
properties  [6,7].  During  the  present  study,  new  dibenzoxepinone  oximes  bearing  fluorinated  and 
trifluoromethylated  substituents  have  been  tested  for  their  antimicrobial  activity,  starting  from  the 
hypothesis  that the  eukariotic  cell  membrane  exhibits  similarities  with  some  prokariotic  structures 
(e.g., the outer membrane of the Gram-negative strains). In this purpose, the new compounds have 
been  tested  comparatively  on  Gram-negative  and  Gram-positive  bacterial  strains  resistant  to  
beta-lactam antibiotics, used in the conventional therapy of this kind of infections. Int. J. Mol. Sci. 2011, 12                       
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The qualitative method used for the screening of the antimicrobial activity of the tested compounds 
indicated only very low diameters of growth inhibition around the paper filter disks, so we did not 
proceed  to  measure  the  diameters  of  the  inhibition  zones.  These  results  could  be  due  to  the  low 
diffusion rates of the tested substances from the paper filter disks. It must also be mentioned that the 
intermediary  compounds  implicated  in  the  synthesis  pathway,  i.e.,  6,11-dihydro-dibenz[b,e]oxepin-
11(6H)-one  and  11-hydroximino-6,11-dihydro-dibenz[b,e]oxepin  have  been  also  screened  by  disk 
diffusion, but no inhibition of the microbial growth was observed. 
The results of the quantitative assay of the antimicrobial activity, expressed by the MIC values, of 
the new compounds are summarized in Figure 1. 
Figure 1. Minimum inhibitory concentration (MIC) of dibenz[b,e]oxepins. 
 
The  quantitative  assay  revealed  that  out  of  the  tested  compounds,  all  were  more  active  that 
ceftazidime, exhibiting lower MIC values than the antibioticon Klebsiella planticola, six on Morganella 
morganii, five on Pseudomonas aeruginosa and two on methicillin resistant Staphylococcus aureus 
(Figure 1). A MIC value superior to 250 µg/mL was considered as corresponding to a low, between 
250 µg/mL and 125 µg/mL to moderate and under 62.5 µg/mL to a good antimicrobial activity. 
In general, the positions of fluorine and trifluoromethyl substituents on phenyl ring significantly 
influenced  the  antibacterial  activity.  It  is  already  known  that  fluorine  could  exhibit  an  intrinsic 
microbicidal activity. Insertion of fluorine in a strategic position of a molecule has emerged as a very 
powerful and versatile tool for the development of the compounds endowed with biological activities. 
The presence of fluorine often leads to increased lipid solubility, thereby enhancing the rate of in vivo 
absorption and transport of drugs [9,10]. 
The  most  active  compound,  concerning  both the  intensity  of  the  antimicrobial  activity  and  the 
microbial  spectrum  proved  to  be  ({[(E/Z)-11-dibenz[b,e]oxepin-11(6H)-ylidene]amino}oxy) 
[2-fluoro-5-(trifluoromethyl)-phenyl]methanone (c), which has been more active than ceftazidime on 
methicillin resistant Staphylococcus aureus, Pseudomonas aeruginosa and Morganella morganii. It 
could be concluded that the substitution with F in position 2 and CF3 in 5 is the most favorable for the Int. J. Mol. Sci. 2011, 12                       
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antimicrobial activity. Interestingly, the reversion of the two subtituents (F in 5 and CF3 in 2) leads to 
the loss of the anti-Staphylococcus activity. 
The 2-F, 4-CF3 (b)  and the 2-F, 5-CF3 (c) disubstituted derivatives exhibited good antibacterial 
activity, superior to ceftazidime and DMSO against Staphylococcus aureus. 
The lowest antimicrobial activity was observed for the substitutions in 3 and 5 positions (e). The 
substitutions in the positions 2 and 4 (b) or 3 and 5 (e) are not favorable for the antimicrobial activity 
against Morganella morganii and Pseudomonas aeruginosa.  
For  Proteus  vulgaris,  Salmonella  arizonae  and  Escherichia  coli,  the  activity  of  the  tested 
compounds  was  similar  to  that  of  the  DMSO  solvent  and  inferior  to  the  control  antibiotic.  For 
Klebsiella planticola, all tested substances showed similar MIC values as for the DMSO and lower 
than the tested antibiotic.  
Although the differences between DMSO and the tested compounds did not exceed one dilution, it 
must be noticed that in some cases, our compounds were more active than ceftazidime. The relatively 
high MIC values could be due, on the other hand, to the fact that the bacterial strains chosen to be 
tested were of clinical origin and resistant to antibiotics.  
3. Experimental Section  
3.1. Chemicals and Methods 
All chemicals and solvents were purchased  from Merck, Fluka and Sigma-Aldrich and were of 
commercial quality. They were used as received, except 1,2-dichloroethane (anhydrized over calcium 
chloride  and  distilled  at  normal  pressure),  pyridine  (stored  over  potassium  hydroxide  and  then 
distilled), and benzene (kept overnight with sodium and then distilled). 
Melting  points  were  uncorrected  and  determined  in  open  capillary  tubes  on  an  Electrothermal  
9100 apparatus. 
Elemental analyses were performed on a Perkin Elmer CHNS/O Analyser Series II 2400 apparatus, 
the results being within ±0.4% of the theoretical values. 
IR spectra were recorded on a FT-IR Bruker Vertex 70 spectrophotometer. 
NMR spectra were recorded on a Varian Unity Inova 400 instrument operating at 400 MHz for 
1H, 
100 MHz for 
13C and 376.279 MHz for 
19F-NMR. 
3.1.1. Synthesis of the New Compounds  
The dibenz[b,e]oxepins were synthesized according to the previusly described procedure [11]. The  
2-phenoxymethylbenzoic acid was prepared in the first stage, by refluxing the phtalide with potassium 
phenoxyde in xylene. This gives the 2-phenoxymethylbenzoic acid potassium salt, which has good 
solubility in potassium hydroxide aqueous solution allowing its facile separation from xylene. The 
aforementioned acid was then precipitated using a mineral acid solution. The potassium salt of phenol 
was obtained using phenol and potassium hydroxide in xylene, the resulting water being removed by 
azeotropic  distillation.  The  6,11-dihydro-dibenz[b,e]oxepin-11(6H)-one  was  synthesized  in  the  
second  stage  by  a  Friedel-Crafts  cyclization  of  the  2-phenoxymethylbenzoic  acid  chloride  in  dry  
1,2-dichloroethane. The acid chloride was obtained by refluxing the corresponding acid with thionyl Int. J. Mol. Sci. 2011, 12                       
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chloride and anhydrous 1,2-dichloroethane as reaction medium. The new compounds were prepared by 
acylation of the 11-hydroximino-6,11-dihydro-dibenz[b,e]oxepin with various substituted benzoic acid 
chlorides, in dry benzene and in the presence of anhydrous pyridine as a proton fixator. The resulting 
solid was recrystallized from isopropanol to yield the new O-acyl-oximino-dibenz[b,e]oxepins. The 
oxime  was  obtained  by  treating  the  6,11-dihydro-dibenz[b,e]oxepin-11(6H)-one  with  hydroxylamine 
hydrochloride  in presence of pyridine. The chemical  structure of the new compounds  is presented  
in Table 1. 
Table 1. Data on the new compounds. 
O
N-O-C-R
O
1
2
3
4
5
6
7
8
9
10
11
12
4a
1a
7a
10a
 
No.  R 
m. p.  
(°C) 
yield 
(%) 
C%  H%  N% 
c.  e.  c.  e.  c.  e. 
a. 
13
14
15
F CF3
16
17 18
19  
149.9–152.4  68  63.62  63.95  3.15  3.17  3.37  3.41 
b.  13
14 15
CF3
F
16
17 18
19
 
115.6–118.7  74  63.62  63.84  3.15  3.16  3.37  3.31 
c. 
13
14 15
F
CF3
16
17
18
19
 
145.1–145.7  78  63.62  63.30  3.15  3.19  3.37  3.39 
d.  13
14 15
CF3
F
16
17 18
19
 
116.5–117.2  82  63.62  63.98  3.15  3.19  3.37  3.31 
e. 
13
14 15
F
CF3
16
17 18
19
 
118.4–119.6  66  63.62  63.29  3.15  3.09  3.37  3.36 
f. 
13
14 15
F
16
17 18
F3C
19  
130.4–133.8  86  63.62  63.89  3.15  3.11  3.37  3.35 
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Table 1. Cont. 
O
N-O-C-R
O
1
2
3
4
5
6
7
8
9
10
11
12
4a
1a
7a
10a
 
No.  R 
m. p.  
(°C) 
yield 
(%) 
C%  H%  N% 
c.  e.  c.  e.  c.  e. 
g. 
13
14 15
F
CF3
16
17 18
19  
137.5–139.6  68  63.62  63.94  3.15  3.18  3.37  3.31 
h.  13
14 15
F
16
17 18
F3C
19  
145.3–147.1  62  63.62  63.31  3.15  3.12  3.37  3.39 
where: c. = calculated, e. = experimental. 
3.1.1.1. ({[(E/Z)-11-dibenz[b,e]oxepin-11(6H)-ylidene]amino}oxy)[2-fluoro-3-(trifluoromethyl)-
phenyl]methanone (a) (E/Z isomers mixture in ratio 1:2.45 estimated by 
1H-NMR) 
FT-IR (solid in ATR, ν cm
−1): 532 (w), 572 (w), 630 (w), 705 (m), 748.(vs), 827 (m), 865 (m), 948 
(w), 979 (m), 1075 (s), 1098 (s), 1122 (vs), 1159 (m), 1195 (s), 1237 (m), 1269 (s), 1305 (m), 1333 (s), 
1443 (m), 1462 (s), 1481 (w), 1595 (m), 1611 (m), 1740 (vs), 2987 (w), 3072 (w), 3104 (w). 
19F-NMR (CDCl3): δ-61.97(3F, d, 
4J(F-15–F-14) = 13.78 Hz, CF3), δ-109.60 (1F, q, 
4J(F-15–F-14) = 13.78 
Hz, F-14). 
1H-NMR  (CDCl3): δ 5.19 (s, H-6 
M), 5.25 (s, H-6 
m), 6.91 (dd, J = 1.1, 8.4 Hz, H-4 
M), 6.98  
(dd, J = 1.1, 8.4 Hz, H-4 
m), 7.02 (ddd, J = 1.1, 7.0, 8.0 Hz, H-2 
M), 7.03 (ddd, J = 1.1, 7.0, 8.0 Hz,  
H-2 
m), 7.29 (1H, m, J(H-17–H-16)= 8.2 Hz, H-17), 7.36 (1H, ddd, J = 1.7, 7.2, 8.4 Hz, H-3), 7.49–7.40 
(3H, m, H-7, H-8, H-9), 7.61 (m, H-10 
M), 7.66 (m, H-10 
m), 7.83–7.73 (m, H-16, H-1 
m), 7.87 (dd,  
J = 1.8, 8.0 Hz, H-1 
M), 8.06 (ddd, J(F-H-18)= 6.5 Hz, J(H-17–H-18)= 8.2 Hz, J(H-18–H-16)= 1.7 Hz, H-18 
M), 
8.13 (ddd, J(F-H-18)= 6.5 Hz, J(H-17–H-18)= 8.2 Hz, J(H-18–H-16)= 1.7 Hz, H-18 
m). 
13C-NMR (CDCl3): δ 70.4 (C-6 
m), 70.5 (C-6 
M), 118.4, 119.2, 119.4, 120.0 
M, 120.4 
m, 120.8 
m, 
121.5 
M, 123.3 (q, J(F-C)= 271.1 Hz, C-19), 124.1 (d, 
3J(F-C) = 4.4 Hz, C-18), 127.2, 127.9 
m, 128.3 
M, 
128.4 
m, 128.5 
M, 129.3 
m, 130.7 
M, 130.9 
M, 131.0 
m, 131.7 (m, C-15), 132.6, 132.8 
m, 132.9 
M, 134.2 
(C-10a 
m), 134.2 (C-10a 
M), 136.0 (C-16 
M), 136.1 (C-16 
m), 155.8 (C-4a 
m), 157.6 (C-4a 
M), 162.1  
(d, J(F-C) = 252.7 Hz, C-14), 165.4 (C-11), 162.7 (C-12). 
3.1.1.2. ({[(E/Z)-11-dibenz[b,e]oxepin-11(6H)-ylidene]amino}oxy)[2-fluoro-4-(trifluoromethyl)-
phenyl]methanone (b) (E/Z isomers mixture in ratio 1:4.3 estimated by 
1H-NMR) 
FT-IR (solid in ATR, ν cm
−1): 545 (w), 602 (w), 634 (w), 698 (w), 756 (s), 835 (w), 882 (m),  
916 (w), 977 (s), 1007 (m), 1049 (m), 1084 (vs), 1127 (s), 1176 (s), 1214 (s), 1236 (m), 1277 (m), Int. J. Mol. Sci. 2011, 12                       
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1304 (m), 1332(s), 1430 (s), 1481 (w), 1507 (w), 1606 (m), 1745 (vs), 2865 (w), 2917 (w), 2993 (w), 
3071 (w). 
19F-NMR (CDCl3): δ-63.90 (3F, bs, CF3), δ-105.11 (1F, bs, F-14). 
1H-NMR (CDCl3): δ 5.19 (s, H-6 
M), 5.25 (s, H-6 
m), 6.91 (dd, J = 1.1, 8.4 Hz, H-4 
M), 6.98 (dd,  
J = 1.1, 8.4 Hz, H-4 
m), 7.02 (1H, td, J = 8.4, 1.1 Hz, H-2), 7.51–7.33 (6H, m, H-3, H-7, H-8, H-9,  
H-15, H-18), 7.59 (1H, m, H-10), 7.88 (1H, dd, J = 1.8, 8.0 Hz, H-1), 7.99 (bt, 
5J(H-17–F-14) = 7.2 Hz,  
3J(H-17–H-18) = 7.2 Hz, H-17 
M), 8.08 (bt, 
5J(H-17–F-14) = 7.2 Hz, 
3J(H-17–H-18) = 7.2 Hz, H-17 
m). 
13C-NMR (CDCl3): δ 70.4 (C-6 
m), 70.5 (C-6 
M), 114.7 (dq, J(F-C-15) = 25.6 Hz, J(F3-C-15) = 3.8 Hz,  
C-15), 119.4 (C-1 ª), 120.0, 121.0 (dq, C-17), 121.5, 123.5 (q, J(F-C) = 272.3 Hz, C-19), 127.2 
M, 127.9 
m, 
128.3 (d, J(F-C) = 2.2 Hz, C-18), 128.4 
M, 128.5 
m, 130.6, 130.9, 132.7, 132.9, 133.2, 134.3, 136.5, 
136.8, 157.6 (C-4 ª), 162.6 (C-11), 162.7 (d, J(F-C) = 245.8 Hz, C-14), 165.5 (C-12). 
3.1.1.3. ({[(E/Z)-11-dibenz[b,e]oxepin-11(6H)-ylidene]amino}oxy)[2-fluoro-5-(trifluoromethyl)-
phenyl]methanone (c) (E/Z isomers mixture in ratio 1:2.2 estimated by 
1H-NMR) 
FT-IR (solid in ATR, ν cm
−1): 548 (w), 616 (w), 681 (w), 753 (s), 794 (w), 847 (m), 895 (m),  
977 (s), 1011 (m), 1038 (vs), 1078 (s), 1110 (s), 1161 (m), 1207 (vs), 1271 (w), 1310 (m), 1334 (s), 
1445 (m), 1483 (w), 1606 (m), 1764 (vs), 2883 (w), 2986 (w), 3070 (w). 
19F-NMR (CDCl3): δ-62.81 (3F, bs, CF3), δ-102.18 (1F, bs, F-14). 
1H-NMR (CDCl3): δ 5.19 (s, H-6 
M), 5.25(s, H-6 
m), 6.91 (dd, J = 1.1, 8.4 Hz, H-4
M), 7.06–6.97 
(m, H-2, H-4 
m), 7.23 (t, J = 7.8 Hz, H-15 
M), 7.28 (t, J = 7.8 Hz, H-15 
m), 7.51–7.32 (5H, m, H-2, H-3,  
H-7, H-8, H-9), 7.60 (bd, J = 7.8 Hz, H-16 
M), 7.76 (bd, 7.8 Hz, H-16 
m), 7.77 (1H, m, H-10), 7.88 
(1H, dd, J = 1.8, 8.0 Hz, H-1), 8.25 (1H, bd, J = 4.9 Hz, H-18). 
13C-NMR (CDCl3): δ 70.5 (C-6 
m), 70.6 (C-6 
M), 118.1 (m, C-15), 119.4(C-1a), 120.0 
M, 120.5 
m, 
120.8 
M, 121.5 
m, 123.1 (q, J(F-C-19) = 270.9 Hz, C-19), 127.2 
m, 127.9 
M, 128.2 
M, 128.5 
m, 128.4 
M, 
128.5 
m, 129.4, 130.0 (m, C-18), 130.6 
M, 130.7 
m, 130.9, 131.9 (m, C-16), 132.7 
M, 132.9 
m, 134.2  
(C-10a 
m),  134.3  (C-10a 
M),  136.7,  157.6  (C-4a),  160.3  (q,  J(CF3-C-17)  =  4.4  Hz,  C-17),  163.5  
(d, J(F-C) = 264.4 Hz, C-14), 164.53 (C-11), 165.4 (C-12). 
3.1.1.4. ({[(E/Z)-11-dibenz[b,e]oxepin-11(6H)-ylidene]amino}oxy)[3-fluoro-4-(trifluoromethyl)-
phenyl]methanone (d) (E/Z isomers mixture in ratio 1:2.4 estimated by 
1H-NMR) 
FT-IR (solid in ATR, ν cm
−1): 561 (w), 591 (w), 609 (w), 641 (w), 673 (w), 705 (w), 727 (m),  
754 (s), 774 (m), 796 (w), 824 (m), 843 (w), 878 (m), 936 (s), 988 (m), 1004 (m), 1045 (s), 1085 (vs), 
1123 (s), 1139 (vs), 1192 (vs), 1222 (m), 1250 (vs), 1281 (m), 1312 (s), 1328 (s), 1378 (w), 1418 (s), 
1443 (m), 1482 (m), 1506 (w), 1583 (m), 1605 (m), 1630 (w), 1761 (vs), 2892 (w), 2965 (w), 3068 (w). 
19F-NMR (CDCl3): δ-62.34 (3F, d, 
4J(3F-16–F-15) = 12.64 Hz, CF3), δ-112.94 (1F, q, 
4J(3F-16–F-15) = 12.64 
Hz, F-15). 
1H-NMR (CDCl3): δ 5.20 (s, H-6 
M), 5.26 (s, H-6 
m), 6.92 (dd, J = 1.2, 8.4 Hz, H-4 
M), 7.03 (dd, J = 
1.2, 8.4 Hz, H-4 
m), 7.03 (ddd; J = 1.2, 7.2, 8.2 Hz, H-2 
M), 7.08 (ddd, J = 1.2, 7.2, 8.2 Hz, H-2 
m), 7.37 Int. J. Mol. Sci. 2011, 12                       
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(1H, ddd, J = 1.4, 7.2, 8.2 Hz, H-3), 7.58–7.33 (4H, m, H-7-, H-8, H-9, H-10), 7.84–7.64 (m, H-1 
m,  
H-14, H-17, H-18), 7.89 (dd, J = 1.8, 8.0 Hz, H-1 
M). 
13C-NMR (CDCl3): δ 70.5 (C-6 
m), 70.6 (C-6 
M), 118.1 (d,  J(F-C) = 22.7 Hz, C-14 
M), 118.3 (d,  
J(F-C) = 22.7 Hz, C-14 
m,), 119.2 (C-1a), 120.1, 121.6, 122.0 (q, J(F-C-19) = 271.6 Hz, C-19), 125.3 (d,  
J(F-C-13) = 4.3 Hz, C-13 
M), 125.4 (d, J(F-C-13) = 4.3 Hz, C-13 
m), 127.2 
m, 127.6, 127.8 
M, 127.9 
m, 128.5 
M, 128.8 
M, 129.4 
m, 130.3, 130.8 (d, J(F-C-18)= 2.8 Hz, C-18), 132.9 
m, 133.0 
M, 134.1 (C-10a 
m), 134.2  
(C-10a 
M), 134.5, 136.7, 156.0 (C-4a 
m), 157.7 (C-4a 
M), 160.3 (q, J(CF3-C-16) = 4.4 Hz, C-16), 159.6  
(d, J(F-C-15) = 254.8 Hz, C-15), 164.6 (C-11), 165.5 (C-12). 
3.1.1.5. ({[(E/Z)-11-dibenz[b,e]oxepin-11(6H)-ylidene]amino}oxy)[3-fluoro-5-(trifluoromethyl)-
phenyl]methanone (e) (E/Z isomers mixture in ratio 1:4.4 estimated by 
1H-NMR)  
FT-IR (solid in ATR, ν cm
−1): 554 (w), 591 (w), 628 (w), 641 (w), 689 (m), 706 (w), 755 (s),  
783 (w), 807 (w), 885 (s), 921 (w), 945 (m), 1002 (m), 1044 (w), 1103 (m), 1137 (vs), 1181 (vs),  
1231 (vs), 1250 (s), 1336 (m), 1352 (m), 1443 (w), 1482 (m), 1607 (m), 1763 (s), 3001 (w), 3079 (w), 
3081 (w). 
19F-NMR (CDCl3): δ-63.51 (3F, bs, CF3), δ-109.19 (1F, bs, F-15). 
1H-NMR (CDCl3): δ 5.20 (s, H-6 
M), 5.26 (s, H-6 
m), 6.92 (dd, J = 1.2, 8.4 Hz, H-4 
M), 7.03 (dd,  
J = 1.2, 8.4 Hz, H-4 
m), 7.03 (ddd, J = 8.2, 7.2, 1.2 Hz, H-2 
M), 7.09 (ddd, J = 8.2, 7.2, 1.2 Hz, H-2 
m), 
7.37 (1H, ddd, J = 1.4, 7.2, 8.2 Hz, H-3), 7.61–7.34 (m, H-7, H-8, H-9, H-10 
m, H-14), 7.68 (m, H-10 
M), 
7.79 (1H, ddd, J = 2.4, 1.8 Hz, J(F-H-16) = 8.6 Hz, H-16), 7.89 (1H, dd, J = 1.8, 8.0 Hz, H-1), 7.92  
(bs, H-18 
M), 8.40 (bs, H-18 
m). 
13C-NMR (CDCl3): δ 70.6 (C-6 
m), 70.6 (C-6
M), 117.6 (dq, J(F-C-16) = 22.7.2 Hz, J(F3-C-16) = 3.7Hz,  
C-16), 119.2 (C-1a), 120.1, 121.6, 121.8 (q, J(F-C-19) = 269.8 Hz, C-19), 122.4 (q, J(F-C) = 3.6 Hz, C-18), 
123.0, 127.8, 128.5, 128.8, 130.3, 130.8, 131.9, 132.0 (d, J(F-C) = 8.0 Hz, C-13), 132.9, 133.0, 134.2 
(C-10a), 157.7 (C-4a), 161.1 (C-11), 162.3 (d, J(F-C-15) = 250.0 Hz, C-15), 165.5 (C-12). 
3.1.1.6. ({[(E/Z)-11-dibenz[b,e]oxepin-11(6H)-ylidene]amino}oxy)[4-fluoro-2-(trifluoromethyl)-
phenyl]methanone (f) (E/Z isomers mixture in ratio 1:3 estimated by 
1H-NMR)  
FT-IR (solid in ATR, ν cm
−1): 547 (w), 579 (w), 632 (m), 688 (w), 753 (s), 878 (m), 910 (m),  
971 (s), 1001 (m), 1037 (s), 1082 (s), 1139 (vs), 1246 (vs), 1310 (s), 1431 (m), 1480 (m), 1604 (m), 
1761 (vs), 2888 (w), 2990 (w), 3071 (w). 
19F-NMR (CDCl3): δ-60.30 (3F, d, 
5J(F-16–3F-19) = 5.74 Hz, CF3), δ-105.30 (1F, q, 
4J(3F-19–F-16) = 5.74 
Hz, F-16). 
1H-NMR (CDCl3): δ 5.19 (s, H-6 
M), 5.25 (s, H-6 
m), 6.90 (dd, J = 1.4, 8.2 Hz, H-4 
M), 6.93 (td,  
J = 8.2, 1.4 Hz, H-2 
m), 6.97 (dd, J = 1.4, 8.2 Hz, H-4 
m), 7.01 (td, J = 8.2, 1.4 Hz, H-2 
M), 7.22–7.49 
(7H, m,  H-3, H-7, H-8, H-9, H-10, H-15, H-17), 7.69 (dd, J(F-H-18) = 5.4 Hz, J(H-18-H-17) = 8.6 Hz,  
H-18 
M), 7.81 (dd, J(F-H-18) = 5.4 Hz, J(H-18-H-17) = 8.6 Hz, H-18 
m), 7.54 (dd, J = 1.8, 8.0 Hz, H-1 
m),  
7.87 (dd, J = 1.8, 8.0 Hz, H-1 
M). Int. J. Mol. Sci. 2011, 12                       
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13C-NMR (CDCl3): δ 70.4 (C-6 
m), 70.48 (C-6 
M), 115.0 (dq, J(F-C-15)= 25.6 Hz, J(F3-C-15)= 5.1 Hz,  
C-15), 118.8 (J(F-C-17)= 21.2 Hz, C-17 
M), 118.8 (J(F-C-17) = 21.2 Hz, C-17 
m), 119.3 (C-1a), 120.0 
M, 
120.5 
m, 120.8 
m, 121.5 
M, 122.2 (q, J(F3-C-19) = 264.3 Hz, C-19), 127.7 
M, 127.9 
m, 128.4
M, 128.5 
m, 
129.4, 130.5, 130.5 
M, 130.7 
m, 130.8, 132.7, 132.9 (dq, J(F-C-14)= 12.4 Hz, J(F3-C-14) = 8 Hz, C-14), 
132.9, 134.0 (C-10a 
m), 134.3 (C-10a 
M), 136.7, 155.8 (C-4a 
m), 157.5 (C-4a 
M), 162.9 (C-11), 163.8 
(d, J(F-C-16) = 253.3 Hz, C-16), 164.6 (C-12 
M), 165.6 (C-12 
m). 
3.1.1.7. ({[(E/Z)-11-dibenz[b,e]oxepin-11(6H)-ylidene]amino}oxy)[4-fluoro-3-(trifluoromethyl)-
phenyl]methanone (g) (E/Z isomers mixture in ratio 1:4.8 estimated by 
1H-NMR) 
FT-IR (solid in ATR, ν cm
−1): 548 (w), 631 (w), 675 (w), 707 (w), 731 (w), 752 (s), 846 (m),  
981 (m), 1006 (w), 1051 (m), 1077 (s), 1108 (w), 1133 (m), 1147 (s), 1161 (s), 1223 (s), 1243 (s), 
1269 (m), 1305 (m), 1325 (s), 1423 (m), 1441 (m), 1464 (w), 1480 (w), 1601 (m), 1759 (vs), 2897 (w), 
2962 (w), 3073 (w). 
19F-NMR (CDCl3): δ-62.24(3F, d, 
4J(3F-15–F-16) = 12.06 Hz, CF3), δ-106.47(1F, q, 
4J(3F-15–F-16) = 12.06 
Hz, F-16). 
1H-NMR  (CDCl3): δ 5.20 (s, H-6 
M), 5.26 (s, H-6 
m), 6.92 (dd, J = 1.4, 8.2 Hz, H-4 
M), 7.03  
(dd, J = 1.4, 8.2 Hz, H-4 
m), 7.04 (td, J = 8.2, 1.4 Hz, H-2 
M), 7.08 (td, J = 8.2, 1.4 Hz, H-2 
m), 7.26 
(dd, J(H-17-H-18) = 8.2 Hz, J(F-H-17)= 10.4 Hz, H-17 
M), 7.29 (dd, J(H-17–H-18) = 8.2 Hz, J(F-H-17) = 10.4 Hz, 
H-17 
m), 7.37  (1H, ddd, J = 1.7, 7.2, 8.0 Hz, H-3), 7.57–7.34  (3H, m, H-7, H-8, H-9), 7.68 (dq,  
J(F-H-14) = 8.0 Hz, J(F3-H-14) = 1.8 Hz, H-14 
M), 7.89 (1H, dd, J = 1.8, 8.0 Hz, H-1), 8.18–8.10 (m, H-10 
M, 
H-18), 8.24 (m, H-14 
m), 8.30 (m, H-10 
m). 
13C-NMR (CDCl3): δ 70.5 (C-6 
m), 70.6 (C-6 
M), 117.6 (d, J(F3-C-17) = 21.2 Hz, C-17), 119.3 (C-1a), 
120.0 (C-4), 121.6 (C-2), 122.0 (q, J(F3-C-19) = 270.3 Hz, C-19), 125.3 (d, J(F-C-13) = 2.9 Hz, C-13), 127.8 
(C-10 
M), 127.9 (C-10 
m), 128.4, 128.7, 129.3 (m, C-15), 130.4, 130.7 (C-1 
m), 130.8, 130.8 (C-1 
M), 
132.8 (C-3 
m), 132.9 (C-3 
M), 133.0, 134.3 (C-10a), 135.8 (d, J(F-C) = 9.5 Hz, C-14), 157.6 (C-4a), 
161.4 (C-11), 162.7 (d, J(F-C-16) = 263.6 Hz, C-16), 166.0 (C-12). 
3.1.1.8. ({[(E/Z)-11-dibenz[b,e]oxepin-11(6H)-ylidene]amino}oxy)[5-fluoro-2-(trifluoromethyl)-
phenyl]methanone (h) (E/Z isomers mixture in ratio 1:2.8 estimated by 
1H-NMR)  
FT-IR(solid in ATR, ν cm
−1): 518 (w), 591 (m), 630 (w), 680 (w), 757 (s), 835 (m), 885 (m),  
932 (m), 984 (m), 1031 (s), 1076 (s), 1115 (vs), 1153 (vs), 1196 (s), 1257 (s), 1305 (vs), 1440 (w), 
1480 (w), 1597 (m), 1759 (vs), 2875 (w), 3078 (w) 
19F-NMR (CDCl3): δ-59.25 (3F, bs, CF3); δ-106.49 (1F, bs, F-14). 
1H-NMR(CDCl3): δ 5.19 (s, H-6 
M), 5.25 (s, H-6 
m), 6.90 (dd, J = 1.4, 8.2 Hz, H-4 
M), 6.94 (td, J = 
8.2, 1.4, H-2 
m), 6.97 (dd, J = 1.4,  8.2  Hz, H-4 
m), 7.02 (td, J = 8.2, 1.4  Hz, H-2 
M),  7.23–7.49  
(6H, m, H-3, H-7, H-8, H-9, H-16, H-18), 7.54 (dd, J = 1.8, 8.0 Hz, H-1 
m), 7.66 (m, H-10 
m), 7.72 (dd, 
J(F-H-15) = 5.1 Hz, J(H-15-H-16) = 8.8 Hz, H-15 
M), 7.76(dd, J(F-H-15) = 5.1 Hz, J(H-15–H-16) = 8.8 Hz, H-15 
m), 
7.86 (dd, J = 1.8, 8.0 Hz, H-1 
M). Int. J. Mol. Sci. 2011, 12                       
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13C-NMR (CDCl3, ppm): δ 70.4 (C-6 
m), 70.5 (C-6 
M), 117.7 (d, J(C-F) = 24.9 Hz, C-18 
M), 117.7 (d, 
J(C-F)= 24.9 Hz, C-18 
m), 118.4 (d, J(C-16-F) = 22.0 Hz, C-16 
M), 118.4 (d, J(C-16-F) = 22.0 Hz, C-16 
m), 
119.5 (C-1a), 120.6, 120.9, 121.5, 127.1, 127.7, 127.9,  128.4, 129.6, 129.5 (dq, J(F-C-14) = 3.8 Hz,  
J(F3-C-14) = 5.1 Hz, C-14), 130.4 
m, 130.6 
M, 130.7 
m, 130.8 
M, 132.7, 132.7 
m, 132.9 
M, 134.1 (C-10a 
m), 
134.2 (C-10a 
M), 155.8 (C-4a 
m), 157.6 (C-4a 
M), 163.9 (d, J(F-C-17) = 241.6 Hz, C-17), 165.1 (C-11), 
165.9 (C-12). 
3.2. Microbiological Assays 
3.2.1. Microbial Strains 
The antimicrobial activity of the investigated compounds was tested against the following bacterial 
strains:  Gram-positive,  coagulase-positive,  methicillin  resistant  Staphylococcus  aureus  1268  and 
Gram-negative,  beta-lactam  resistant  Pseudomonas  aeruginosa  1246,  Morganella  morganii  2,  
Proteus vulgaris 12, Salmonella arizonae 23, Klebsiella planticola 8 and Escherichia coli 13147 strains.  
The coagulase-positive, methicillin resistant Staphylococcus aureus and the Pseudomonas aeruginosa 
strain  were  recently  isolated  from  central  venous  catheters  associated  infections,  while  the 
Enterobacteriaceae strains were isolated from different cases of acute diffuse peritonitis. 
All tested strains were identified by VITEK I automatic system. VITEK cards for identification and 
susceptibility  testing  (GNS-522)  were  inoculated  and  incubated  according  to  the  manufacturer’s 
recommendations.  The  results  were  interpreted  by  using  software  version  AMS  R091.  Bacterial 
suspensions  of  density  corresponding  to  0.5  McFarland  UI  obtained  from  18  h  bacterial  cultures 
developed  on  solid  media  were  used  in  the  experiments.  The  antimicrobial  activity  of  the  new 
compounds was tested on Mueller-Hinton agar medium.  
3.2.2. Stock Solutions 
The tested compounds were solubilised in DMSO and used for the antimicrobial activity screening 
at 1 mg/ mL concentration. 
3.2.3. Qualitative Screening of the Antimicrobial Properties of the Tested Compounds  
The qualitative screening was performed by an adapted disk diffusion method. In this purpose, Petri 
dishes with Mueller Hinton medium were seeded with bacterial inoculum as for the classical antibiotic 
susceptibility  testing  (Kirby-Bauer  method);  5 mm  diameter  paper  filter  disks  were  placed  on the 
seeded medium, at 30 mm distance. Subsequently, the disks were impregnated with 5 μL of the stock 
solution. The plates were left at room temperature for 20–30 min and then incubated at 37 °C for 24 h. 
The positive results were read as the occurrence of an inhibition zone of microbial growth around the 
disk [12–14]. 
3.2.4. Quantitative Assay of the Antimicrobial Activity 
It was performed by binary micro dilution method, in Mueller Hinton broth (MHB) distributed in  
96 multi-well plates, in order to establish the minimum inhibitory concentration (MIC) [15–17]. In this Int. J. Mol. Sci. 2011, 12                       
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purpose, serial binary dilutions of the tested compounds were performed in a 150 μL volume of MHB 
(from 1000 μg/mL to 7.8 μg/mL) and each well was seeded with 30 μL of microbial inoculum of  
0.5 MacFarland density. The plates were incubated for 24 h at 37 °C, and MICs were read as the last 
concentration of the compound which inhibited the visual microbial growth.  
3.2.5. Antibiotic Controls 
Beta-lactam  antibiotics  (i.e.,  third  generation  cephalosporin  ceftazidime)  have  been  used  as  
controls [15].  
4. Conclusions  
In conclusion, we synthesized some new dibenz[b,e]oxepin derivatives from the key intermediate 
11-hydroximino-6,11-dihydro-dibenz[b,e]oxepin,  which  was  treated  with  acyl  chloride  in  order  to 
obtain eight compounds bearing fluorine and trifluoromethyl group substituents in different positions 
on  the  phenyl  ring.  The  results  of  the  antibacterial  activity  of  the  new  compounds  indicated  that  
the most active was the 2-F, 5-CF3 substituted one, which exhibited good antimicrobial activity against 
multi-drug  resistant  strains  of  Pseudomonas  aeruginosa,  enterobacterial  strains  and  methicillin 
resistant S. aureus, frequently implicated in the etiology of opportunistic infections.  
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